Factors Associated with the Development of Skeletal-related Events in Non-small Cell Lung Cancer Patients with Bone Metastases

J. Wei,T. Jun,Z. Pinghai,L. Hui,H. Qunying,B. Chunxue,W. Qun,Z. Zhaochong
DOI: https://doi.org/10.1016/j.ijrobp.2011.06.1118
2011-01-01
Abstract:The purpose of this study was to identify the predictive factors of skeletal-related events (SREs) in NSCLC patients with bone metastases. Time-to-the first SRE and SRE-free survival and their associations with the patient characteristics were evaluated retrospectively in 416 patients in NSCLC with bone metastatic. Univariate and multivariate statistical methods were used to determine significant risk factors for SRE-free survival. The overall median survival time was 11.5 (9.9-13.2) months from bone metastases. The median observation period for SREs was 8.9 (7.9-9.9) months. Out of 416 patients with bone metastases, 159 (38.2%) developed at least one SRE during or after the initial treatment. On univariate analysis, patients with characteristics such as male, nonadenocarcinoma, ever-smoking, bone metastases with soft-tissue extension and no history of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) therapy had a shorter median time from bone metastasis to first SRE. The results of multivariate analysis revealed that male, bone metastases with soft-tissue extension, no history of EGFR-TKI therapy risk factors for the first SRE, with hazard ratios (HRs) (95% confidence interval [CI]) 1.414 (1.050-1.905), 1.225 (1.030-1.457), 1.731 (1.327-2.259), respectively. The presence of bone metastases with soft-tissue extension was significantly associated with the development of SREs in patients with advanced NSCLC. Male sex and no history of EGFR-TKI therapy were also independent risk factor of development of SREs throughout the course of disease.Tabled 1Analyses of time from bone metastasis to first skeletal-related eventCharacteristicNo of patientstime to event (months)Univariate(P)Multivariate(P)Gender0.0000.023Female15510.7Male2617.7Age0.3710.986> = 60 years2609.8< 60 years1568.0Smoking0.0020.786Ever1547.6Never26210.0Histology0.0210.447Adenocarcinoma3239.8Nonadenocarcinoma936.0Soft-tissue extension0.0000.022Yes1495.9No23811.1Not clear2915.0EGFR-TKI therapy0.0000.000Yes12413.7NO2927.7 Open table in a new tab
What problem does this paper attempt to address?